OncoCyte (OCX) Shares Gap Down to $5.20

Share on StockTwits

Shares of OncoCyte Corp (NYSEAMERICAN:OCX) gapped down prior to trading on Thursday . The stock had previously closed at $4.80, but opened at $5.20. OncoCyte shares last traded at $4.98, with a volume of 9640 shares changing hands.

Several analysts recently issued reports on the company. Lake Street Capital upped their target price on OncoCyte from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research lowered OncoCyte from a “buy” rating to a “hold” rating in a report on Saturday, January 26th. Finally, assumed coverage on OncoCyte in a report on Monday, October 29th. They set a “positive” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $5.33.

OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.

A hedge fund recently raised its stake in OncoCyte stock. Vanguard Group Inc grew its position in OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 410,275 shares of the biotechnology company’s stock after purchasing an additional 15,115 shares during the quarter. Vanguard Group Inc owned about 1.01% of OncoCyte worth $1,026,000 as of its most recent SEC filing.

COPYRIGHT VIOLATION WARNING: “OncoCyte (OCX) Shares Gap Down to $5.20” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4115881/oncocyte-ocx-shares-gap-down-to-5-20.html.

About OncoCyte (NYSEAMERICAN:OCX)

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Featured Article: Coverage Ratio

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Verisk Analytics, Inc.  Director Andrew G. Mills Sells 3,000 Shares
Verisk Analytics, Inc. Director Andrew G. Mills Sells 3,000 Shares
Hunt Companies Finance Trust Inc  Raises Dividend to $0.07 Per Share
Hunt Companies Finance Trust Inc Raises Dividend to $0.07 Per Share
Direxion Daily 7-10 Year Treasury Bull 3x Shares  Announces $0.11 Quarterly Dividend
Direxion Daily 7-10 Year Treasury Bull 3x Shares Announces $0.11 Quarterly Dividend
Direxion MSCI Cyclicals Over Defensives ETF  Declares $0.15 Special Dividend
Direxion MSCI Cyclicals Over Defensives ETF Declares $0.15 Special Dividend
Direxion Daily CSI 300 China A Share Bear 1x Shares  Raises Dividend to $0.45 Per Share
Direxion Daily CSI 300 China A Share Bear 1x Shares Raises Dividend to $0.45 Per Share
Orion Group  Hits New 12-Month Low at $3.64
Orion Group Hits New 12-Month Low at $3.64


© 2006-2019 Ticker Report